应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
TLPH Talphera Inc.
休市中 05-31 16:00:00 EDT
1.03
+0.01
+0.98%
盘后
1.03
+0.00
0.00%
18:40 EDT
最高
1.05
最低
1.00
成交量
9,002
今开
1.01
昨收
1.02
日振幅
4.90%
总市值
1,750万
流通市值
1,311万
总股本
1,699万
成交额
9,230
换手率
0.07%
流通股本
1,273万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Talphera 公司报告截至 12 月的季度业绩 - 收益摘要
Reuters · 03-07
Talphera 公司报告截至 12 月的季度业绩 - 收益摘要
Acelrx Pharmaceuticals Inc盘中异动 快速拉升5.16%报0.841美元
自选股智能写手 · 01-10
Acelrx Pharmaceuticals Inc盘中异动 快速拉升5.16%报0.841美元
加载更多
公司概况
公司名称:
Talphera Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Talphera, Inc.最初于2005年7月13日在特拉华州注册为SuRX,Inc.。该公司随后更名为AcelRx制药,公司于2024年1月10日由“AcelRx Pharmaceuticals, Inc.”更名为“Talphera,Inc.”。该公司是一家专业制药公司,专注于开发和商业化用于医疗监管环境的创新疗法。Talphera的主要候选产品Niyad是一种nafamostat的冻干制剂,目前正在根据研究装置豁免(IDE)作为体外回路的抗凝血剂进行研究,并已获得FDA的突破性装置指定状态。Talphera还在开发两款获得合作伙伴Aguettant许可的预填充注射器:Fedsyra,一种预填充麻黄碱注射器,以及PFS-02,一种预填充去氧肾上腺素注射器。
发行价格:
--
{"stockData":{"symbol":"TLPH","market":"US","secType":"STK","nameCN":"Talphera Inc.","latestPrice":1.03,"timestamp":1717185600000,"preClose":1.02,"halted":0,"volume":9002,"hourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"18:40 EDT","volume":123,"amount":128.083,"timestamp":1717195202602},"delay":0,"floatShares":12726142,"shares":16992977,"eps":-0.801264,"marketStatus":"休市中","marketStatusCode":7,"change":0.01,"latestTime":"05-31 16:00:00 EDT","open":1.01,"high":1.05,"low":1,"amount":9229.8280172,"amplitude":0.04902,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.801264,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1717401600000},"adr":0,"listingDate":1297400400000,"adjPreClose":1.02,"postHourTrading":{"tag":"盘后","latestPrice":1.03,"preClose":1.03,"latestTime":"18:40 EDT","volume":123,"amount":128.083,"timestamp":1717195202602},"volumeRatio":0.19737245937972117},"requestUrl":"/m/hq/s/TLPH","defaultTab":"news","newsList":[{"id":"2417522449","title":"Talphera 公司报告截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2417522449","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2417522449?lang=zh_cn&edition=full","pubTime":"2024-03-07 07:25","pubTimestamp":1709767519,"startTime":"0","endTime":"0","summary":" * Talphera Inc 报告,截至12月底的季度调整后每股亏损25美分,高于去年同期的每股收益1.00美元。两位分析师对该季度的平均预期是每股亏损 20 美分。华尔街预期为每股-24美分至-16美分。* 营收同比增长 11.5%,达到 281.00 万美元;分析师预期为 281.00 万美元。* Talphera Inc 公布的本季度每股收益为亏损 25 美分。* 该公司当季亏损 452 万美元。* Talphera Inc 的股价本季度上涨了 70.1%。* 华尔街对 Talphera Inc 的 12 个月目标价中位数为 5.13 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2402152428","title":"Acelrx Pharmaceuticals Inc盘中异动 快速拉升5.16%报0.841美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2402152428","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2402152428?lang=zh_cn&edition=full","pubTime":"2024-01-10 02:02","pubTimestamp":1704823379,"startTime":"0","endTime":"0","summary":"北京时间2024年01月10日02时02分,Acelrx Pharmaceuticals Inc股票出现波动,股价急速上涨5.16%。截至发稿,该股报0.841美元/股,成交量11.2777万股,换手率0.67%,振幅7.69%。Acelrx Pharmaceuticals Inc股票所在的制药行业中,整体涨幅为0.09%。Acelrx Pharmaceuticals Inc公司简介:AcelRx Pharmaceuticals Inc 是一家专业制药公司,专注于在医学监督环境中使用的疗法的开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240110020300861c979f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240110020300861c979f&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.talphera.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.03},{"period":"3month","weight":-0.2137},{"period":"6month","weight":0.3482},{"period":"1year","weight":-0.055},{"period":"ytd","weight":0.4014}],"compareEarnings":[{"period":"1week","weight":-0.0039},{"period":"1month","weight":0.054},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.1487},{"period":"1year","weight":0.2502},{"period":"ytd","weight":0.1095}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Talphera, Inc.最初于2005年7月13日在特拉华州注册为SuRX,Inc.。该公司随后更名为AcelRx制药,公司于2024年1月10日由“AcelRx Pharmaceuticals, Inc.”更名为“Talphera,Inc.”。该公司是一家专业制药公司,专注于开发和商业化用于医疗监管环境的创新疗法。Talphera的主要候选产品Niyad是一种nafamostat的冻干制剂,目前正在根据研究装置豁免(IDE)作为体外回路的抗凝血剂进行研究,并已获得FDA的突破性装置指定状态。Talphera还在开发两款获得合作伙伴Aguettant许可的预填充注射器:Fedsyra,一种预填充麻黄碱注射器,以及PFS-02,一种预填充去氧肾上腺素注射器。","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.129415},{"month":2,"riseRate":0.461538,"avgChangeRate":0.014533},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.112848},{"month":4,"riseRate":0.571429,"avgChangeRate":0.021324},{"month":5,"riseRate":0.428571,"avgChangeRate":0.062191},{"month":6,"riseRate":0.461538,"avgChangeRate":0.006489},{"month":7,"riseRate":0.307692,"avgChangeRate":0.019298},{"month":8,"riseRate":0.461538,"avgChangeRate":0.00117},{"month":9,"riseRate":0.461538,"avgChangeRate":-0.022386},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.100174},{"month":11,"riseRate":0.615385,"avgChangeRate":0.097895},{"month":12,"riseRate":0.230769,"avgChangeRate":-0.099646}],"exchange":"NASDAQ","name":"Talphera Inc.","nameEN":"Talphera Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.5","shortVersion":"4.22.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Talphera Inc.(TLPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Talphera Inc.(TLPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Talphera Inc.,TLPH,Talphera Inc.股票,Talphera Inc.股票老虎,Talphera Inc.股票老虎国际,Talphera Inc.行情,Talphera Inc.股票行情,Talphera Inc.股价,Talphera Inc.股市,Talphera Inc.股票价格,Talphera Inc.股票交易,Talphera Inc.股票购买,Talphera Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Talphera Inc.(TLPH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Talphera Inc.(TLPH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}